一分钟看懂
这是一项关于非小细胞肺癌的I 期 / II 期研究，登记的药物或干预包括Divarasib；Pembrolizumab；Carboplatin；Cisplatin；Pemetrexed，当前状态为招募中。登记地点显示中国长沙、哈尔滨、上海有研究中心记录。是否仍有名额以及是否值得进一步询问，需要向研究中心确认。
药物或干预
Divarasib；Pembrolizumab；Carboplatin；Cisplatin；Pemetrexed · I 期 / II 期
登记条件中文摘要
年龄范围：18岁及以上
登记的基本范围为不限性别，年龄18岁及以上；以下仅摘录6项专业入选条件，需结合英文原文并由研究团队确认。
登记记录列出8项主要排除条件，具体医学含义需结合英文原文并由研究团队确认。
中国哪些地方有记录
以下地点来自登记信息，不代表此刻仍有名额；请向研究中心确认最新情况。
- Hunan Cancer Hospital · 长沙
- Harbin Medical University Cancer Hospital · 哈尔滨
- Shanghai Pulmonary Hospital · 上海
入选条件原文摘录
以下为摘录，请打开原始登记查看完整入排标准。
- * Confirmation of Biomarker eligibility
- * Pre-treatment tumor tissue along with an associated pathology report is required for all participants enrolled on study. Representative tumor specimens must be in formalin-fixed, paraffin embedded (FFPE) blocks (preferred) or 15 unstained, freshly cut, serial slides. Although 15 slides are required, if only 10 slides are available, the participant may be eligible for the study following consultation with the Sponsor.
- * Eastern Cooperative Oncology Group (ECOG) performance status (PS) of 0 or 1
- * Histologically or cytologically documented locally advanced unresectable or metastatic NSCLC that is not eligible for curative surgery and/or definitive chemoradiotherapy
- * No prior systemic treatment for advanced unresectable or metastatic NSCLC
- * Measurable disease, as defined by Response Evaluation Criteria in Solid Tumors (RECIST) v1.1. Additionally, for participants in cohort D, measurable brain metastases defined as at least 5 millimeters and twice the slice thickness, but less than 20 mm, that is asymptomatic and does not require local therapy at the time of enrollment.
联系前需要确认
请继续确认中心是否启动、疾病分型、既往治疗、检查费用和知情同意安排。
查看登记信息
登记号：NCT05789082；登记信息更新于 2026-10-06；本站同步于 2026-10-08，中国中心当前名额未经人工确认。